Advertisement

Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation

Published:October 17, 2016DOI:https://doi.org/10.1016/j.cgh.2016.10.011

      Background & Aims

      Gastrointestinal (GI) bleeding in patients receiving anticoagulation agents can be caused by occult malignancies. We investigated the proportions and features of major GI bleeding (MGIB) events related to occult GI cancers in patients receiving anticoagulation therapy.

      Methods

      We analyzed data from the Randomized Evaluation of Long Term Anticoagulant Therapy study (conducted between December 2005 and March 2009 in 951 clinical centers in 44 countries worldwide), which compared the abilities of dabigatran vs warfarin to prevent stroke and systemic embolism in 18,113 patients with atrial fibrillation. Two blinded gastroenterologists independently reviewed source documents of MGIB events (n = 595) that occurred during the study period. We collected data on MGIB events caused by previously unidentified GI malignancies, and compared characteristics of MGIB events in patients who received dabigatran vs warfarin (primary end point), and in patients with bleeding from cancer, vs patients bleeding from a nonmalignant or unidentified source.

      Results

      Of 546 unique MGIB events, 44 (8.1%) were found to be from GI cancers (34 of 398 MGIB events in dabigatran users and 10 of 148 MGIB events in warfarin users; P = .60). Colorectal cancer accounted for 35 of 44 of all cancers identified. There were more colorectal cancer–associated MGIB events in the dabigatran group (30 of 34) than in the warfarin group (5 of 10) (P = .02), but more gastric cancer–associated MGIB events in the warfarin group (5 of 10) than in the dabigatran group (1 of 34) (P = .001). There were no differences in the short-term outcomes of cancer-related MGIB events in the dabigatran vs the warfarin group, but 75% of all cancer-related MGIB events required at least 1 blood transfusion and the mean hospital stay was 10.1 days. Compared with MGIB events from a nonmalignant or unidentified source, MGIB from cancer occurred sooner (343.0 vs 223.1 d; P = .003), but the bleeding was more likely to be chronic (for >7 d) (27.3% vs 63.6%; P < .001).

      Conclusions

      In evaluating data from a study of the effects of anticoagulation therapy, we found approximately 1 of every 12 MGIB events to be related to an occult cancer. Approximately two thirds of cancer-related MGIB presents with chronic bleeding, and morbidity, and resource utilization is high.

      Keywords

      Abbreviations used in this paper:

      AF (atrial fibrillation), CRC (colorectal cancer), DOAC (direct oral anticoagulant), FOBT (fecal occult blood test), GI (gastrointestinal), Hgb (hemoglobin), ICU (intensive care unit), MGIB (major gastrointestinal bleeding), NSAID (nonsteroidal anti-inflammatory drug), OAC (oral anticoagulant), RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy trial), VKA (vitamin K antagonist)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Petersen P.
        • Boysen G.
        • Godtfredsen J.
        • et al.
        Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.
        Lancet. 1989; 1: 175-179
        • Connolly S.J.
        • Ezekowitz M.D.
        • Yusuf S.
        • et al.
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151
        • Giugliano R.P.
        • Ruff C.T.
        • Braunwald E.
        • et al.
        Edoxaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2013; 369: 2093-2104
        • Patel M.
        • Mahaffey K.
        • Garg J.
        • et al.
        Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
        N Engl J Med. 2011; 365: 883-891
        • Granger C.B.
        • Alexander J.H.
        • McMurray J.J.V.
        • et al.
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Ruff C.T.
        • Giugliano R.P.
        • Braunwald E.
        • et al.
        Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.
        Lancet. 2014; 383: 955-962
        • Graham D.J.
        • Reichman M.E.
        • Wernecke M.
        • et al.
        Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
        Circulation. 2015; 131: 157-164
        • Eikelboom J.W.
        • Wallentin L.
        • Connolly S.J.
        • et al.
        Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) Trial.
        Circulation. 2011; 123: 2363-2372
        • Sherid M.
        • Sifuentes H.
        • Sulaiman S.
        • et al.
        Gastrointestinal bleeding with dabigatran, a comparative study with warfarin: a multicenter experience.
        Korean J Gastroenterol. 2015; 65: 205-214
        • Desai J.
        • Granger C.B.
        • Weitz J.I.
        • et al.
        Novel oral anticoagulants in gastroenterology practice.
        Gastrointest Endosc. 2013; 78: 227-239
        • Bini E.J.
        • Rajapaksa R.C.
        • Weinshel E.H.
        Positive predictive value of fecal occult blood testing in persons taking warfarin.
        Am J Gastroenterol. 2005; 100: 1586-1592
        • Johannsdottir G.A.
        • Onundarson P.T.
        • Gudmundsdottir B.R.
        • et al.
        Screening for anemia in patients on warfarin facilitates diagnosis of gastrointestinal malignancies and pre-malignant lesions.
        Thromb Res. 2012; 130: e20-e25
        • McCall K.L.
        • MacLaughlin E.J.
        Warfarin-associated bleeding complication saved life.
        Pharmacotherapy. 2002; 22: 265-268
        • Michaels M.M.
        Bleeding from occult tumors during anticoagulant therapy.
        Circulation. 1962; 25: 804-806
        • Norton S.
        • Armstrong C.
        Lower gastrointestinal bleeding during anticoagulant therapy: a life-saving complication?.
        Ann R Coll Surg Engl. 1997; 79: 38-39
        • Jaffin B.W.
        • Bliss C.M.
        • LaMont J.T.
        Significance of occult gastrointestinal bleeding during anticoagulation therapy.
        Am J Med. 1987; 83: 269-272
        • Clemens A.
        • Strack A.
        • Noack H.
        • et al.
        Anticoagulant-related gastrointestinal bleeding—could this facilitate early detection of benign or malignant gastrointestinal lesions?.
        Ann Med. 2014; 46: 672-678
        • Ezekowitz M.D.
        • Connolly S.
        • Parekh A.
        • et al.
        Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran.
        Am Heart J. 2009; 157 (810 e1-e2): 805-810
        • Schulman S.
        • Kearon C.
        Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.
        J Thromb Haemost. 2005; 3: 692-694
        • Connolly S.J.
        • Ezekowitz M.D.
        • Yusuf S.
        • et al.
        Newly identified events in the RE-LY trial.
        N Engl J Med. 2010; 363: 1875-1876
        • Hashash J.G.
        • Shamseddeen W.
        • Skoury A.
        • et al.
        Gross lower gastrointestinal bleeding in patients on anticoagulant and/or antiplatelet therapy: endoscopic findings, management, and clinical outcomes.
        J Clin Gastroenterol. 2009; 43: 36-42
        • Mozaffarian D.
        • Benjamin E.J.
        • Go A.S.
        • et al.
        Heart disease and stroke statistics—2016 update.
        Circulation. 2015; 132: 1-324
        • January C.T.
        • Wann L.S.
        • Alpert J.S.
        • et al.
        2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
        Circulation. 2014; 130: 2071-2104
        • Manatsathit W.
        • Al-Hamid H.
        • Leelasinjaroen P.
        • et al.
        Management of gastrointestinal bleeding in patients anticoagulated with dabigatran compared with warfarin: a retrospective, comparative case review.
        Cardiovasc Diagn Ther. 2014; 4: 224-231
        • Ghate S.R.
        • Biskupiak J.
        • Ye X.
        • et al.
        All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation.
        J Manag Care Pharm. 2011; 17: 672-684
        • Mandelli G.
        • Radaelli F.
        • Paggi S.
        • et al.
        Anticoagulant or aspirin treatment does not affect the positive predictive value of an immunological fecal occult blood test in patients undergoing colorectal cancer screening: results from a nested in a cohort case-control study.
        Eur J Gastroenterol Hepatol. 2011; 23: 323-326
        • Goss A.M.
        • van Ryn J.
        • Schurer J.
        • et al.
        Assessment of cross-reactivity in three different fecal occult blood test systems with dabigatran and dabigatran etexilate: identification of useful test methods.
        Blood. 2012; 120: 4360
      1. COUMADIN ® (warfarin sodium). Full prescribing information. Bristol-Myers Squibb Pharma, Princeton, NJ2015 (Available from:) (Published December 2016. Accessed: January 12, 2016)
      2. PRADAXA® (dabigatran etexilate mesylate). Full prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT2015 (Available from:) (Accessed: January 12, 2016)
        • Blech S.
        • Ebner T.
        • Ludwig-Schwellinger E.
        • et al.
        The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.
        Drug Metab Dispos. 2008; 36: 386-399
        • James M.W.
        • Chen C.M.
        • Goddard W.P.
        • et al.
        Risk factors for gastrointestinal malignancy in patients with iron-deficiency anaemia.
        Eur J Gastroenterol Hepatol. 2005; 17: 1197-1203
        • Mandel J.S.
        • Church T.R.
        • Ederer F.
        • et al.
        Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.
        J Natl Cancer Inst. 1999; 91: 434-437
        • Mandel J.S.
        • Bond J.H.
        • Church T.R.
        • et al.
        Reducing mortality from colorectal cancer by screening for fecal occult blood.
        N Engl J Med. 1993; 328: 1365-1371
        • Guerrouij M.
        • Uppal C.S.
        • Alklabi A.
        • et al.
        The clinical impact of bleeding during oral anticoagulant therapy: assessment of morbidity, mortality and post-bleed anticoagulant management.
        J Thromb Thrombolysis. 2011; 31: 419-423
        • Pollack Jr., C.V.
        • Reilly P.A.
        • Eikelboom J.
        • et al.
        Idarucizumab for dabigatran reversal.
        N Engl J Med. 2015; 373: 511-520